Article Text


S95 Exploiting the immunoregulatory role of Siglec-E via sialic acid-functionalised nanoparticles as a novel approach for the treatment of acute lung injury
  1. MK Greene,
  2. S Spence,
  3. F Fay,
  4. D Small,
  5. D Schmid,
  6. J Jaworski,
  7. JF Burrows,
  8. CM O'Kane,
  9. A Kissenpfennig,
  10. DF McAuley,
  11. CJ Scott
  1. Queen's University Belfast, Belfast, United Kingdom


Acute Lung Injury (ALI) is a life-threatening disorder underpinned by dysregulated inflammatory cascades, with resultant injury to lung architecture. Currently, provision of supportive care represents the mainstay of treatment for ALI and novel anti-inflammatory therapeutic strategies are urgently required. We have developed a polymeric nanoconstruct surface-functionalised with sialic acid targeting moieties (SNP), exploiting the anti-inflammatory effects arising from the targeted engagement of Siglec-E receptors on activated macrophages, with potential therapeutic utility in ALI.

Polylactic-co-glycolic acid (PLGA) nanoparticles of uniform size distribution (approximately 150nm in diameter) were synthesised in accordance with a salting-out formulation. Intratracheal instillation of 20μg lipopolysaccharide (LPS) was utilised as a model of ALI in C57BL/6 mice, co-administered with 1μg SNP or non-functionalised nanoparticles (NP). Bronchoalveolar lavage (BALF) samples were collected 24 hours after treatment for analysis by enzyme-linked immunosorbent assay (ELISA).

As exemplified in Figure 1., intratracheal instillation of SNP significantly attenuated BALF levels of pro-inflammatory TNFα and IL-6 cytokines, in addition to the neutrophil chemoattractant KC. Moreover, BALF differential cell counts revealed a decrease in neutrophil numbers upon treatment with SNP under LPS-induced pro-inflammatory conditions. Further analyses addressing the therapeutic utility of SNP have been undertaken, including lung wet/dry ratios, histology and toxicological evaluation, with promising outcomes.

Abstract S95 Figure 1.

Therapeutic efficacy of SNP in a murine model of LPS-induced ALI (* p<0.05, **p<0.001, ***p<0.001 compared to LPS control, as established by one-way ANOVA and Tuley post-hoc test).

This research clearly demonstrates the ability of SNP to diminish the inflammatory response in a murine model of LPS-induced ALI. Considering that chemoattractants and cytokines are key mediators in the pathogenesis of ALI, these results substantiate the credibility of this nanoscaffold as a therapy for ALI. Ultimately, we aim to progress this modality to a human setting, specifically analysing its effects on alveolar macrophages isolated from human volunteers, before advancing to a human ex vivo lung perfusion model.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.